Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalubuminuric patients with type II diabetes

被引:22
|
作者
Shigihara, T
Sato, A
Hayashi, K
Saruta, T
机构
[1] Mito Red Cross Hosp, Dept Internal Med, Mito, Ibaraki 3100011, Japan
[2] Keio Univ, Dept Internal Med, Tokyo, Japan
关键词
type II diabetes mellitus; essential hypertension; angiotensin-converting enzyme inhibitor; calcium channel blocker; microalbuminuria;
D O I
10.1291/hypres.23.219
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
It has been demonstrated that antihypertensive treatment of hypertensive diabetic patients is quite effective in preventing macrovascular and microvascular complications and improving prognosis. Nevertheless, the target blood pressure level of antihypertensive treatment in hypertensive diabetic patients with microalbuminuria (i.e., with early diabetic nephropathy) remains to be established. In this study, we evaluated the effect of intensive blood pressure control (diastolic blood pressure <80 mmHg) on urinary albumin excretion in hypertensive, type II diabetic patients with microalbuminuria. We examined the effects of a combination therapy using an angiotensin converting enzyme (ACE) inhibitor plus a long-acting calcium channel blocker (amlodipine), and compared them with the effect of an ACE inhibitor alone. Thirty hypertensive, type II diabetic patients with microalbuminuria were treated with either an ACE inhibitor alone (group I, n=17) or an ACE inhibitor plus amlodipine (group II, n=13) for 32 weeks. With treatment, blood pressures in both groups were significantly reduced, and diastolic blood pressure was lowered to a much greater extent in group II (76 +/- 2 mmHg) than in group I (83 +/- 2 mmHg, p < 0.05). Although the urinary albumin excretion rate was decreased in both groups, the decrease attained statistical significance only in group II (from 141 +/- 25 mg/day to 69+/-18 mg/day, p<0.05); the extent of reduction in microalbuminuria during antihypertensive treatment was significantly greater in group II (50+/-10%) than in group 1 (14+/-13%, p<0.05). In conclusion, this study showed that in hypertensive microalbuminuric type II diabetic patients, the combination of an ACE inhibitor plus amlodipine resulted in a more pronounced decreased in blood pressure (diastolic blood pressure <80 mmHg) and a greater reduction in urinary albumin excretion than did use of an ACE inhibitor alone. This combination strategy should thus be a more effective tool for obtaining optimal blood pressure control in patients with diabetic nephropathy.
引用
收藏
页码:219 / 226
页数:8
相关论文
共 50 条
  • [21] Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats
    Yamada, T
    Kuno, A
    Ogawa, K
    Tang, MX
    Masuda, K
    Nakamura, S
    Ando, T
    Okamoto, T
    Ohara, H
    Nomura, T
    Joh, T
    Shirai, T
    Itoh, M
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 313 (01): : 36 - 45
  • [22] Beneficial Effects of Combination Therapy with Angiotensin II Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor on Vascular Endothelial Function
    Satoshi Morimoto
    Kei Maki
    Yasuko Aota
    Takao Sakuma
    Toshiji Iwasaka
    Hypertension Research, 2008, 31 : 1603 - 1610
  • [23] Beneficial Effects of Combination Therapy with Angiotensin II Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor on Vascular Endothelial Function
    Morimoto, Satoshi
    Maki, Kei
    Aota, Yasuko
    Sakuma, Takao
    Iwasaka, Toshiji
    HYPERTENSION RESEARCH, 2008, 31 (08) : 1603 - 1610
  • [24] Cardiorenal protective effects of year-long anti hypertensive therapy with a angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats
    Ishimitsu, Toshihiko
    Honda, Takeaki
    Ohta, Satoshi
    Akashiba, Akira
    Takahashi, Toshiaki
    Kameda, Tomoko
    Yoshii, Masayoshi
    Minami, Junichi
    Takahashi, Masaki
    Ono, Hidehiko
    Matsuoka, Hiroaki
    AMERICAN JOURNAL OF HYPERTENSION, 2006, 19 (12) : 1233 - 1240
  • [25] Combined therapy with an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor in heart failure
    Struckman, DR
    Rivey, MP
    ANNALS OF PHARMACOTHERAPY, 2001, 35 (02) : 242 - 248
  • [26] One-year persistence of fixed-dose combinations of angiotensin-converting enzyme inhibitor and calcium channel blocker in hypertensive patients
    Simonyi Gabor
    Ferenci Tamas
    Finta Ervin
    Igaz Ivan
    Balogh Sandor
    Gasparics Roland
    Medvegy Mihaly
    ORVOSI HETILAP, 2019, 160 (09) : 343 - 348
  • [27] Is Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Combination Therapy Better Than Monotherapy and Safe in Patients With CKD?
    Berns, Jeffrey S.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 53 (02) : 192 - 196
  • [28] A combination of calcium channel blocker and angiotensin-converting enzyme inhibitor achieves a target blood pressure of &lt;130/80 mmHg in half of hypertensive diabetics:: The azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study
    Katayama, S.
    Kawamori, R.
    Iwamoto, Y.
    Saito, I.
    Kuramoto, K.
    JOURNAL OF HYPERTENSION, 2008, 26 : S210 - S210
  • [29] Calcium channel blocker decreases urinary albumin and other proteins excretion in hypertensive patients
    Takechi, S.
    Fujimoto, T.
    Machida, M.
    Kakinoki, S.
    Kanda, K.
    Hashimoto, M.
    Nomura, A.
    JOURNAL OF HYPERTENSION, 2007, 25 : S118 - S118
  • [30] Ventricular and vascular remodelling - Effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients
    Petrovic, J
    Petrovic, D
    Vukovic, N
    Zivanovic, B
    Dragicevic, J
    Vasiljevic, Z
    Babic, R
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2005, 33 : 39A - 49A